Alfa Cytology, a biomedical research support provider, has announced an expansion of its radiopharmaceutical development service portfolio by integrating custom radiolabeling for antibody-drug conjugates (ADCs) and targeted radiopharmaceuticals with physicochemical characterization services. The move addresses growing demands in precision medicine, where radiopharmaceuticals are increasingly used for cancer diagnosis and targeted therapy.
According to the company, the integration enables researchers to access coordinated support from radiolabeling through critical quality attribute assessment. This includes evaluation of radiochemical purity, stability, lipophilicity (LogP/LogD), and immunoreactivity. By covering these key activities, Alfa Cytology aims to help clients generate reliable data for candidate evaluation and subsequent studies, thereby improving development efficiency and reducing uncertainty.
Radiopharmaceuticals have become a vital area in precision medicine, with applications ranging from pharmacokinetic studies to molecular imaging. The rapid development of ADCs, peptide therapeutics, and targeted small molecules has increased the need for advanced radiopharmaceutical capabilities. However, successful radiolabeling alone is insufficient; key attributes like purity and target-binding capability require further evaluation. Alfa Cytology's integrated services address this challenge by providing a seamless workflow.
In radiolabeling, the company offers custom radiolabeling for ADCs and targeted radiopharmaceuticals, supporting antibodies, ADCs, peptides, small molecules, and other compounds. The service accommodates various radionuclides for diagnostic and therapeutic use, applicable to pharmacokinetics, biodistribution, molecular imaging, and drug development.
Complementing this, Alfa Cytology provides radiopharmaceutical physicochemical characterization CRO services, analyzing parameters such as radiochemical purity, stability, lipophilicity, and immunoreactivity. These systematic studies help research teams evaluate candidate properties and generate data to support subsequent activities.
“The demand for high-quality radiolabeling and physicochemical characterization data continues to grow as radiopharmaceutical development advances,” said a company spokesperson. “By integrating our technical capabilities, we aim to provide customers with more efficient research support and help advance the development of innovative radiopharmaceuticals and targeted therapies.”
The enhanced portfolio is expected to benefit biotechnology companies, pharmaceutical firms, and academic institutions by streamlining radiopharmaceutical development, reducing the risk of late-stage failures, and accelerating the translation of novel therapies from bench to bedside.
